GLP-1 and Mental Health: What Studies Say About Addiction and Depression

Picture someone like Maria, a few weeks into a Mounjaro dose increase. She tells her sister the food noise has finally gone quiet. The constant chatter about what to eat next has faded. Then she asks the question that has been nagging at her: if the drug can turn down thoughts about food, could it also turn down the wine she reaches for after work, or the flat mood that settles in on Sunday evenings? That question sits at the center of GLP-1 and mental health research, and the honest answer is that we are still early in figuring it out.

Why researchers suspect GLP-1 drugs reach the brain's reward system

GLP-1 is a hormone the gut releases after meals, but its receptors are not limited to the gut and pancreas. Reviews that map GLP-1 receptors in the brain tend to place them in the hypothalamus and brainstem, areas that help regulate appetite. Some work also points toward circuits tied to reward and dopamine signaling, which is why researchers started asking whether these drugs could affect cravings. Still, finding a receptor on a map is not the same as seeing an effect on behavior.

Mounjaro differs from semaglutide in one key way. According to its prescribing information, tirzepatide activates two receptors: GIP and GLP-1. Semaglutide, the active ingredient in Wegovy and Ozempic, acts mainly on GLP-1. That difference matters for research because a dual agonist may influence the brain through an additional pathway. Whether that changes cravings is still unknown.

Here is the plain version. Receptor presence does not prove an effect on craving. It gives researchers a hypothesis, and hypotheses need testing. Scientists still need controlled experiments to show whether drug exposure changes the urge to drink, smoke, or use other substances, and whether that change holds up in people.

What the addiction research looks like so far

Most of the early evidence comes from animal data. In rodent studies, researchers gave GLP-1 drugs and measured how much alcohol, nicotine, or other substances the animals self-administered. Several of these studies reported less self-administration. Animal work is useful for generating ideas, but rodents don't share human cravings, social settings, or drug metabolism, so the results can't be transferred directly to patients.

Human evidence is smaller. Small trials and observational studies have looked at alcohol use disorder and some other dependencies. Before you trust any figure, check the trial name, the registry number on ClinicalTrials.gov or an equivalent registry, the year, the sample size, and the primary endpoint. Also find out whether the results were peer-reviewed or only presented at a conference. Conference talks can be interesting, but they usually come with less detail to check.

As of the sources checked for this post, no GLP-1 drug holds approval from the FDA or the European Medicines Agency for treating substance use disorder. Regulatory status changes, so confirm it on the agency websites on the day you read this.

Depression, mood, and suicidal thoughts in trials and labels

Clinical trials record psychiatric events as adverse events. The main tirzepatide programs, SURMOUNT for obesity and SURPASS for type 2 diabetes, report these in adverse event tables. Look at those tables in the published papers, where depression and suicidal ideation are listed separately from nausea or fatigue. Use the rates printed in the paper itself, not numbers from memory or a social media thread.

Regulators have examined the suicidality question too. In January 2024, the FDA said its review of several GLP-1 medicines for weight management had not found evidence that they cause suicidal thoughts. The agency also noted that the review was ongoing and that the data had limits. Check the current Mounjaro label for its warnings language, since the label is the official document prescribers use and it gets updated over time.

Quality of life is another measure in these studies. Obesity trials often use validated questionnaires such as IWQOL-Lite, which asks how weight affects daily life. Read the paper for the exact changes it reports, not a summary of them. Weight loss, changed eating, nausea, and the stress of managing diabetes can all shape mood on their own. Those effects are real, but they are separate from any direct drug effect on the brain, so keep them apart when you read.

Why the numbers are hard to read

People with obesity or type 2 diabetes already have higher rates of depression than the general population. If you compare GLP-1 users with everyone else, you mix the drug's effect with those baseline differences. Stronger studies compare matched groups.

Who gets prescribed a drug also matters. People who receive a GLP-1 may differ in income, access to care, and existing conditions. Researchers call this indication bias, and it can distort observational results. A patient who starts treatment may also be monitored more closely, which changes what gets recorded.

Reverse causation is another trap. Depression can reduce appetite, medication adherence, and physical activity, and those changes then shape weight and the apparent effect of the drug. Nausea, vomiting, and poor sleep can lower mood too, and they can easily be mistaken for a direct brain effect. Confounding and reverse causation are standard concepts in epidemiology, so look for matching or statistical adjustment in the methods section before you trust a headline.

Questions to bring to your prescriber

Before you start, tell your prescriber about any past depression, suicidal thoughts, eating disorders, alcohol use, or mental health treatment you receive now. These answers change how your doctor monitors you. They are not a judgment, and honest answers make monitoring useful.

• Which symptoms should make me call you, and how quickly?
• How often should we check my mood during dose increases?
• Would a screening questionnaire, such as the PHQ-9, be part of my follow-up?

The PHQ-9 is a nine-item questionnaire published by Kroenke, Spitzer, and Williams in 2001. Each item is scored from 0 to 3, the total ranges from 0 to 27, and a score of 10 or higher is commonly used as a cutoff for further evaluation of depression. Check the original paper if you need the exact details. Our reading guide on talking to your doctor about Mounjaro, found at our reading guide on talking to your doctor about Mounjaro, walks through how to prepare these conversations.

If you have thoughts of harming yourself, don't wait for your next appointment. In Brazil, call CVV at 188, free and any time. In the United States, call or text 988. Anywhere else, contact your local emergency number.

What is still unknown

Most GLP-1 programs measure results in months, not years. The first SURMOUNT obesity trial ran for 72 weeks, which is about a year and a half. That is useful, but it is not long enough to judge rare psychiatric effects or mood changes that appear after many years. Check the follow-up length in each paper and say the limit plainly when you share it.

Data for adolescents, older adults, and people with serious psychiatric illness are thinner. Verify which populations the main trials included before assuming the results apply to you. Also check who funded each study and what the authors disclose. Industry funding is common in this field, and the disclosure section is where you start judging how much weight a result deserves. The MounjaBlog team's approach to reading trial tables covers these checks in more detail.

A press release is not the same as a peer-reviewed paper. When a headline appears, ask three things: who was studied, for how long, and compared to what? If the answers are vague, wait for the full paper before drawing conclusions.

If you feel stuck

The addiction evidence is early and mostly preclinical. Animal studies suggest a possible role, small human studies are preliminary, and no one should expect a GLP-1 drug to cure alcohol use disorder or any other dependency. The depression data need careful reading, since trials record psychiatric events but observational studies face heavy confounding. The drug may help some people with weight and blood sugar, and it might affect mood differently from one person to the next.

One practical step helps more than it sounds. Keep a simple notebook. Each day, note your mood on a 1 to 5 scale, your sleep, any nausea, cravings, and drinking. Then bring it to your prescriber. Patterns across several weeks tell you far more than one bad day does. A MounjaBlog mood log template can give you the columns to start with.

FAQ

Does Mounjaro cause depression?

Current evidence does not establish that Mounjaro causes depression, and the FDA has not found evidence that these medicines cause suicidal thoughts. Still, any new or worsening mood change deserves a call to your prescriber.

Can Mounjaro reduce alcohol cravings?

Animal studies suggest a possible effect, and small human studies are early. As of the sources checked for this post, no GLP-1 drug is approved for alcohol use disorder.

Should I stop Mounjaro if my mood drops?

Don't stop on your own. Contact your prescriber soon so they can assess what is happening. If you have thoughts of self-harm, call 188 in Brazil or 988 in the United States right away.

Sources

• Mounjaro (tirzepatide) Prescribing Information, Eli Lilly and Company
• FDA Drug Safety and Availability
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine, 2022
• Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a Brief Depression Severity Measure, Journal of General Internal Medicine, 2001
• ClinicalTrials.gov, U.S. National Library of Medicine
• PubMed, National Library of Medicine (search for GLP-1 receptor distribution and reviews of central GLP-1 signaling)
• 988 Suicide and Crisis Lifeline
• Centro de Valorização da Vida (CVV), Brasil